Skip to main content
SpringerLink
Log in

Prognosis and therapy of myelodysplastic syndromes

  • Chapter
Book cover Leukemia: Advances in Research and Treatment

Part of the book series: Cancer Treatment and Research ((CTAR,volume 64))

  • 57 Accesses

Abstract

This chapter will deal primarily with issues faced by physicians in the management of patients with myelodysplastic syndromes (MDSs). Accordingly, emphasis will be placed on assessing these patients’ prognoses and the therapeutic options available in light of these prognoses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennett JM, Catovsky D, Daniel MT, et al. (1985). Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103: 626–629.

    Google Scholar 

  2. Rheingold JJ, Kaufman R, Adelson E, Lear A (1963). Smoldering acute leukemia. N Engl J Med 268: 812–815.

    Article  PubMed  CAS  Google Scholar 

  3. Rheingold JJ (1974). Acute leukemia, its smoldering phase or Leukemia never starts on Thursday. JAMA 230: 985–986.

    Article  PubMed  CAS  Google Scholar 

  4. Mufti GJ, Stevens JR, Oscier DG, et al. (1985). Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59: 425–433.

    Article  PubMed  CAS  Google Scholar 

  5. Sanz GH, Sanz MA, Vallespi T, et al. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74: 395–408.

    PubMed  CAS  Google Scholar 

  6. Bennett JM, Catovsky D, Daniel MT, et al. (1976). Proposals for the classification of the acute leukaemias. Br J Haematol 33: 451–458.

    Article  PubMed  CAS  Google Scholar 

  7. Foucar K, Langdon RM, Armitage JO, et al. (1985). Myelodysplastic syndromes: A clinical and pathologic analysis of 109 cases. Cancer 56: 553–561.

    Article  PubMed  CAS  Google Scholar 

  8. Vallespi T, Torrabadella M, Julia A, et al. (1985). Myelodysplastic syndromes: a study of 101 cases according to the FAB Classification. Br J Haematol 61: 83–92.

    Article  PubMed  CAS  Google Scholar 

  9. Jacobs RH, Cornbleet MA, Vardiman JW, et al. (1986). Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 67: 1765–1772.

    PubMed  CAS  Google Scholar 

  10. Kerkhofs H, Hermans J, Haak HL, et al. (1987). Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 65: 73–81.

    Article  PubMed  CAS  Google Scholar 

  11. Varela BL, Chuang C, Bennett JM (1982). Clinical significance of the new proposals for the classication of the myelodysplastic syndromes. Blood 60(Suppl 1):140e (abstract).

    Google Scholar 

  12. van der Weide M, Sizoo W, Nauta JJP, et al. (1980). Myelodysplastic syndromes: analysis of clinical and prognostic features in 96 patients. Eur J Haematol 41: 115–122.

    Article  Google Scholar 

  13. Coiffier B, Adeleine P, Gentilhomme O, et al. (1987). Myelodysplastic syndromes: A multiparametric study of prognostic factors in 336 patients. Cancer 60: 3029–3032.

    Article  PubMed  CAS  Google Scholar 

  14. Maddox AM, Keating MJ, Smith TL, et al. (1986). Prognostic factors for survival of 194 patients with low infiltrate leukemia. Leuk Res 10: 995–1006.

    Article  PubMed  CAS  Google Scholar 

  15. Yoshida Y, Oguma S, Uchino M (1991). Long-term survival of refractory myelodysplastic anemias. N Engl J Med 325: 662.

    PubMed  CAS  Google Scholar 

  16. Tricot G, Boogaerts MA, DeWolf-Peeters C, et al. (1985). The myelodysplastic syndromes: different evolution patterns based on morphological and cytogenetic investigations. Br J Haematol 59: 659–670.

    Article  PubMed  CAS  Google Scholar 

  17. Borgström GH (1986). Cytogenetics of the myelodysplastic syndromes. Scand J Haematol 36(Suppl 45):74–77.

    Google Scholar 

  18. Weh HJ, Calavezos A, Seeger D, et al. (1987). Cytogenetics studies in 69 patients with myelodysplastic syndromes (MDS). Eur J Hamatol 38: 166–172.

    Article  CAS  Google Scholar 

  19. Knapp RH, Dewald GW, Pierre RV (1985). Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes: Mayo Clin Proc 60: 507–516.

    PubMed  CAS  Google Scholar 

  20. Yunis JJ, Lobell M, Arnesen MA, et al. (1988). Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 68: 189–194.

    Article  PubMed  CAS  Google Scholar 

  21. Pierre RV, Catovsky D, Jufti GJ, et al. (1989). Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 40: 149–161.

    Article  PubMed  CAS  Google Scholar 

  22. Bloomfield CD (1986). Chromosome abnormalities in secondary myelodysplastic syndromes. Scand J Haematol 36(Suppl 45):82–90.

    Google Scholar 

  23. Van den Berghe H (1986). The 5q-syndrome. Scand J Haematol 36(Suppl 45):78–81.

    Google Scholar 

  24. Estey EH, Keating MJ, Dixon DO, et al. (1987). Karyotype is prognostically more important than the FAB system’s distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol Pathol 1: 203–208.

    PubMed  CAS  Google Scholar 

  25. Raymakers R, DeWitte T, Joziasse J, et al. (1991). In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukaemia. Br J Haematol 78: 35–41.

    Article  PubMed  CAS  Google Scholar 

  26. Galton DAG (1986). The myelodysplastic syndromes. Scand J Haematol 36(Suppl 45):11–20.

    Google Scholar 

  27. Elias L, Hoffman R, Boswell S, et al. (1987). A trial of recombinant α2 interferon in the myelodysplastic syndromes: 1. Clinical results. Leukemia 1: 105–110.

    CAS  Google Scholar 

  28. Freireich E, Gehan E, Sulman D, et al. (1961). The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 14: 593–608.

    Article  PubMed  CAS  Google Scholar 

  29. Hong WK, Lippman SM, Itri L, et al. (1990). Prevention of second primary tumors with isotretinon in squamous-cell carcinoma of the head and neck. N Engl J Med 323: 795–801.

    Article  PubMed  CAS  Google Scholar 

  30. Warrell RP, Frankel SR, Miller WH, et al. (1991). Differentiation therapy of acute promyelocytic leukemia with tretinoin (All-trans-retinoic acid). N Engl J Med 324: 1385–1393.

    Article  PubMed  Google Scholar 

  31. Muindi J, Frankel SR, Miller WH, et al. (1992). Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid ‘resistance’ in patients with acute promyelocytic leukemia. Blood 79: 299–303.

    PubMed  CAS  Google Scholar 

  32. Breitman TR, Selonick SE, Collins SJ (1980). Induction of differentiation of the human promyelocytic leukemia cell line (HL60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936.

    Article  PubMed  CAS  Google Scholar 

  33. Gold EJ, Mertelsmann RH, Itri LM, et al. (1983). Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep 67: 981–986.

    PubMed  CAS  Google Scholar 

  34. Greenberg BR, Durie BGM, Barnett TC, et al. (1985). Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome. Cancer Treat Rep 69: 1369–1374.

    PubMed  CAS  Google Scholar 

  35. Abrahm J, Besa EC, Hyzinski M, et al. (1986). Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis-retinoic acid in a patient with myelodysplastic symdrome: inhibition of growth of the patient’s malignant monocytoid clone. Blood 67: 1323–1327.

    PubMed  CAS  Google Scholar 

  36. Picozzi VJ, Swanson GF, Morgan R, et al. (1986). 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol 4: 589–595.

    PubMed  Google Scholar 

  37. Kerndrup G, Bendix-Hansen K, Pedersen B, et al. (1987). 13-cis retinoic acid treatment of myleodysplastic syndromes. Leuk Res 11: 7–16.

    Article  PubMed  CAS  Google Scholar 

  38. Clark RE, Lush CH, Jacobs A, et al. (1987). Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet 1: 763–765.

    Article  PubMed  CAS  Google Scholar 

  39. Koeffler HP, Heitjan D, Mertelsmann R, et al. (1988). Randomized study of 13-cis-retinoic acid v placebo in the myelodysplastic disorders. Blood 71: 703–708.

    PubMed  CAS  Google Scholar 

  40. Vadhan-Raj S, Keating M, LeMaistre A, et al. (1987). Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1552.

    Article  PubMed  CAS  Google Scholar 

  41. Ganser A, Völkers B, Greher J, et al. (1989). Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes—a phase I-II trial. Blood 73: 31–37.

    PubMed  CAS  Google Scholar 

  42. Thompson JA, Lee DJ, Kidd P, et al. (1989). Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 7: 629–637.

    PubMed  CAS  Google Scholar 

  43. Estey E, Kurzrock R, Talpaz M, et al. (1989). Therapy of myelodysplastic syndromes (MDS) with GM-CSF. Proc ASCO 8: 200 (abstract).

    Google Scholar 

  44. Estey E, Kurzrock R, Talpaz M, et al. (1991). Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 77: 291–295.

    Article  PubMed  CAS  Google Scholar 

  45. Antin JH, Smith BR, Holmes W, et al. (1988). Phase I-II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 72: 705–713.

    PubMed  CAS  Google Scholar 

  46. Herrmann F, Lindemann A, Klein H, et al. (1989). Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 3: 335–338.

    PubMed  CAS  Google Scholar 

  47. Estey E, Thall PF, Kantarjian H, et al. (1992). Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 79: 2246–2255.

    PubMed  CAS  Google Scholar 

  48. Schuster AA, Thompson JA, Larson R, et al. (1990). Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) versus observation in patients with myelodysplastic syndrome or aplastic anemia. Proc ASCO 9: 205.

    Google Scholar 

  49. Negrin RS, Haeuber DH, Nagler A, et al. (1989). Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 110: 976–984.

    PubMed  CAS  Google Scholar 

  50. Negrin RS, Haeuber DH, Nagler A, et al. (1990). Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76: 36–43.

    PubMed  CAS  Google Scholar 

  51. Kobayashi Y, Okabe T, Ozawa K, et al. (1989). Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A preliminary report. Am J Med 86: 178–182.

    Article  PubMed  CAS  Google Scholar 

  52. Yoshida Y, Hirashima H, Asano S, et al. (1991). A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 78: 378–384.

    Article  PubMed  CAS  Google Scholar 

  53. Ganser A, Seipelt G, Lindemann A, et al. (1990). Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76: 455–462.

    PubMed  CAS  Google Scholar 

  54. Kurzrock R, Talpaz M, Estrov Z, et al. (1991). Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9: 1241–1250.

    PubMed  CAS  Google Scholar 

  55. Eschbach JW, Egrie JC, Downing MR, et al. (1987). Correct of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 316: 73.

    Article  PubMed  CAS  Google Scholar 

  56. Stein RS, Abels RI, Krantz SB (1991). Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78: 1658–1663.

    PubMed  CAS  Google Scholar 

  57. Kurzrock R, Talpaz M, Estey E, et al. (1991). Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 5: 985–990.

    PubMed  CAS  Google Scholar 

  58. Kanz L, Brugger W, Bross K, et al. (1991). Combination of cytokines: current status and future prospects. Br J Haematol 79(Suppl 1):96–104.

    Article  PubMed  Google Scholar 

  59. Berry DA (1987). Interim analysis in clinical trials: the role of the likelihood principle. Am Statistician 41: 117–122.

    Google Scholar 

  60. Wisch JS, Griffin JD, Kufe DW (1983). Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 309: 1599–1602.

    Article  PubMed  CAS  Google Scholar 

  61. Bolwell BJ, Cassileth PA, Gale RP (1987). Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1: 575–579.

    PubMed  CAS  Google Scholar 

  62. Cheson BD, Jasperse DM, Simon R, et al. (1986). A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4: 1857–1864.

    PubMed  CAS  Google Scholar 

  63. Mertelsmann R, Thaler HT, To L (1980). Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56: 773–781.

    PubMed  CAS  Google Scholar 

  64. Armitage JO, Dick FR, Needleman SW, et al. (1981). Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 65: 601–605.

    PubMed  CAS  Google Scholar 

  65. Tricot G, Boogaerts MA (1986). The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 63: 477–483.

    Article  PubMed  CAS  Google Scholar 

  66. Preisler HD, Raza A, Barcos M, et al. (1986). High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study. Am J Hematol 23: 131–134.

    Article  PubMed  CAS  Google Scholar 

  67. Fenaux P, Lai JL, Jouet JP, et al. (1988). Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 57: 297–302.

    Article  PubMed  CAS  Google Scholar 

  68. Fenaux P, Morel P, Rose C, et al. (1991). Prognostic factors in adult de novo myelodysplastic syndromes treated by intestive chemotherapy. Br J Haematol 77: 497–501.

    Article  PubMed  CAS  Google Scholar 

  69. Michels SD, Saumur J, Arthur DC, et al. (1989). Refractory anemia with excess of blasts in transformation-hematologic and clinical study of 52 patients. Cancer 64: 2340–2346.

    Article  PubMed  CAS  Google Scholar 

  70. Appelbaum FR, Barrall J, Storb R (1990). Bone marrow transplantation for patients with myelodysplasia: pretreatment variables and outcome. Ann Intern Med 590–597.

    Google Scholar 

  71. O’Donnell MR, Nademanee AP, Snyder DS, et al. (1987). Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 5: 1822–1826.

    PubMed  Google Scholar 

  72. Belanger R, Gyger M, Perreault C, et al. (1988). Bone marrow transplantation for myelodysplastic syndromes. Br J Haematol 69: 29–33.

    Article  PubMed  CAS  Google Scholar 

  73. DeWitte T, Zwaan F, Herman J, et al. (1989). Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Bone Marrow Transplant (Suppl 3):38–39.

    Google Scholar 

  74. Bunin NJ, Casper JT, Chitambar C, et al. (1988). Partially matched bone marrow transplantation in patients with myelodsplastic syndromes. J Clin Oncol 6: 1851–1855.

    PubMed  CAS  Google Scholar 

  75. Clift RA, Buckner CD, Thomas ED, et al. (1987). The treatment of acute nonlymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2: 243–258.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Elihu H. Estey
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, The University of Texas, USA

    Emil J. Freireich  & Hagop Kantarjian  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Estey, E.H. (1993). Prognosis and therapy of myelodysplastic syndromes. In: Freireich, E.J., Kantarjian, H. (eds) Leukemia: Advances in Research and Treatment. Cancer Treatment and Research, vol 64. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3086-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3086-2_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6348-4

  • Online ISBN: 978-1-4615-3086-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation